Familial pulmonary fibrosis: Genetics, testing, and family risk

Familial pulmonary fibrosis is a type of pulmonary fibrosis (PF) that runs in families and is sometimes linked to an underlying inherited genetic mutation.

In PF, scarring (fibrosis) in the lungs makes breathing more difficult, leading to symptoms such as shortness of breath, cough, and fatigue. It is a progressive type of interstitial lung disease (ILD), a group of respiratory conditions characterized by lung inflammation, scarring, or both.

The most common type of PF is idiopathic pulmonary fibrosis (IPF), which has no clear underlying cause. Familial PF may account for up to 20% of PF cases. While it may often progress and be treated similarly to IPF, this diagnosis comes with special considerations for family screening and genetic testing.

While familial PF is the generally accepted term for PF that runs in families, other terms — such as genetic PF, inherited PF, and hereditary PF — may be used in certain contexts where PF is linked to inherited genetic factors.

What is familial PF?

Familial PF is generally defined as a fibrotic ILD that is present in at least two first- or second-degree blood relatives. First-degree relatives include parents, children, and siblings, while second-degree relatives include grandparents, grandchildren, aunts, uncles, nieces, and nephews.

While an inherited disease-causing genetic mutation underlies about one-third of these cases, no such mutation is identified in others. If the appropriate family history is present, an identifiable genetic mutation is not required for a familial PF diagnosis.

Moreover, not all affected family members will necessarily have the exact same type of ILD. While some family members may be diagnosed with IPF, others may have an alternate ILD diagnosis.

The symptoms of familial PF are generally similar to those of IPF, with lung function declining over time. However, familial PF often starts at a younger age.

Is PF hereditary?

Genetic factors are thought to play an important role in PF development. The prevalence of PF is 10 times higher among families with a known PF diagnosis.

However, researchers believe that genetics interacts with environmental factors to cause familial PF. In other words, while hereditary mutations increase the risk, they alone might not cause PF to develop. Not everyone with a disease-associated mutation will develop PF. For example, people with disease-related mutations may have a lower risk of developing the condition if they do not smoke.

Which genes are linked to familial PF?

In recent decades, researchers have learned much about the genetics of familial PF, and several mutations have been linked to the disease. These mutations most often affect one of two types of genes:

  • Telomere-related genes
  • Surfactant-related genes

However, much remains unknown, and many families with PF do not have a clear, identifiable disease-causing genetic mutation.

Telomere-related genes

A telomere is a genetic sequence that caps the end of a chromosome, which is the structure cells use to store DNA, to protect it from damage. Each time a cell divides, its telomeres become shorter. Telomere shortening is linked to the natural process of aging.

A group of proteins called the telomerase complex helps maintain telomeres by adding genetic material to their ends as they shorten. Mutations affecting these proteins can interrupt this process and may contribute to excessive scar tissue formation in familial PF. Telomere genes linked to PF include:

  • TERT
  • TERC
  • DKC1
  • NAF1
  • PARN
  • RTEL1
  • TINF2
  • ZCCHC8

Together, mutations in these genes account for about 30% of familial PF cases. Mutations in several of these genes may also contribute to short telomere syndrome, an inherited condition characterized by telomere dysfunction. PF is a possible manifestation of short telomere syndrome, which can also cause blood abnormalities, changes in liver function, and significant graying of hair before age 30.

Surfactant-related genes

Pulmonary surfactant is a slippery substance that helps protect the lungs and enables their tiny air sacs to expand easily, making breathing easier. Mutations in surfactant genes can contribute to familial PF, including changes in:

  • SFTPA1
  • SFTPA2
  • SFTPC
  • ABCA3
  • TTF1

These mutations are less common causes of familial PF than telomere genes, accounting for about 1%-3% of cases.

Scroll horizontally to view all columns -->

Gene category Key associated genes Familial PF share Biological function
Telomere-related genes TERT, TERC, DKC1, NAF1, PARN, RTEL1, TINF2, ZCCHC8 ~30% of cases Protects chromosome ends from progressive damage; mutations can also cause short telomere syndrome, premature graying, and liver or blood changes
Surfactant-related genes SFTPA1, SFTPA2, SFTPC, ABCA3, TTF1 1% to 3% of cases Produces and regulates pulmonary surfactant, the substance that keeps alveoli (air sacs) open and flexible during normal breathing
Unidentified / other mutations Undiscovered or non-standard variants Up to 70% of cases A negative genetic test does not rule out familial PF if two or more qualifying biological relatives have a diagnosed fibrotic ILD

Who should consider genetic testing?

People who may want to consider genetic testing for PF include those with:

  • A fibrotic ILD and at least one first- or second-degree relative with the condition
  • A first-degree relative with a known PF-causing genetic mutation
  • Suspected short telomere syndrome
  • A fibrotic ILD without a known cause before age 50

In these situations, genetic testing can identify mutations that could cause familial PF.

Should relatives be screened?

Practices regarding family screening for PF vary, but one strategy is cascade testing. After someone tests positive for a potential PF-causing genetic mutation, cascade testing involves screening their first-degree relatives for the same mutation. Then, if one of them also tests positive, that person’s first-degree relatives can receive testing, and so on.

This family testing is voluntary and should ideally be accompanied by genetic counseling, in which a trained professional guides families on who should be tested, what to expect from the testing process, and how to interpret the results.

Understanding PF risk can help individuals plan for the future and make lifestyle changes to protect the lungs, for example, by avoiding smoking.

If genetic screening is unavailable or no disease-causing mutation is found, but there is evidence suggesting familial PF, relatives may want to undergo clinical screening for early signs of lung problems.

What can genetic test results reveal?

Genetic testing can sometimes identify a mutation that explains why PF runs in families. This can help inform care and a family testing plan. However, it is important to understand that the test alone may not be sufficient to determine whether a person will have familial PF.

Up to 70% of familial PF cases do not have an identifiable mutation, so a negative genetic test result doesn’t necessarily mean a person will not develop the disease.

On the other hand, a positive test result for a PF-associated mutation does not necessarily mean someone will develop PF. Some mutations have incomplete penetrance, meaning that having the mutation does not cause PF in every person.

Sometimes, a person may test positive for a PF-related mutation without a clear family history. There are several possible reasons for this, and the terminology surrounding this is still evolving.

How is familial PF treated?

Generally, treatment for familial PF resembles that for other types of PF, although the process is individualized. Several antifibrotic drugs are approved to help slow lung function decline in people with IPF, but their applicability in familial PF may depend on regional regulations.

Oxygen therapy and pulmonary rehabilitation are non-drug therapeutic approaches that may ease symptoms. A lung transplant may be an option for some people with familial PF, particularly in more advanced cases.

Questions to ask the care team or genetic counselor

Healthcare providers and genetic counselors can help individuals and families better understand familial PF and recommend next steps for family testing. A few things to ask include:

  • Whether they have a known disease-associated mutation and, if so, what that means for themselves and their family members
  • The prognosis associated with their specific type of familial PF
  • Whether there are other concerns about familial ILD or short telomere syndrome that they or their family should be aware of
  • How to approach family planning decisions

Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

FAQs about familial PF